197 related articles for article (PubMed ID: 31346130)
1. Analysis of Differentially Expressed MicroRNAs and Circulating Tumor Cells as Predictive Biomarkers of Platinum Chemoresistance in Primary Ovarian Carcinomas: A Prospective Study.
Lou E; Vogel RI; Hoostal S; Wong P; Grad A; Monu M; Łukaszewski T; Deshpande J; Dickson EL; Klein M; Linden MA; Subramanian S; Teoh D; Geller MA
Oncologist; 2019 Nov; 24(11):1422-e1013. PubMed ID: 31346130
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
3. ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.
Chebouti I; Kuhlmann JD; Buderath P; Weber S; Wimberger P; Bokeloh Y; Hauch S; Kimmig R; Kasimir-Bauer S
Oncotarget; 2017 Apr; 8(15):24303-24313. PubMed ID: 28388557
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients.
Liu JF; Kindelberger D; Doyle C; Lowe A; Barry WT; Matulonis UA
Gynecol Oncol; 2013 Nov; 131(2):352-6. PubMed ID: 23954902
[TBL] [Abstract][Full Text] [Related]
5. Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients.
Eitan R; Kushnir M; Lithwick-Yanai G; David MB; Hoshen M; Glezerman M; Hod M; Sabah G; Rosenwald S; Levavi H
Gynecol Oncol; 2009 Aug; 114(2):253-9. PubMed ID: 19446316
[TBL] [Abstract][Full Text] [Related]
6. Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer.
Poveda A; Kaye SB; McCormack R; Wang S; Parekh T; Ricci D; Lebedinsky CA; Tercero JC; Zintl P; Monk BJ
Gynecol Oncol; 2011 Sep; 122(3):567-72. PubMed ID: 21664658
[TBL] [Abstract][Full Text] [Related]
7. EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy.
Chebouti I; Kasimir-Bauer S; Buderath P; Wimberger P; Hauch S; Kimmig R; Kuhlmann JD
Oncotarget; 2017 Jul; 8(30):48820-48831. PubMed ID: 28415744
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of circulating tumor cells (CTCs) captured by microfluidic device in patients with epithelial ovarian cancer.
Lee M; Kim EJ; Cho Y; Kim S; Chung HH; Park NH; Song YS
Gynecol Oncol; 2017 May; 145(2):361-365. PubMed ID: 28274569
[TBL] [Abstract][Full Text] [Related]
9. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
Hartmann LC; Lu KH; Linette GP; Cliby WA; Kalli KR; Gershenson D; Bast RC; Stec J; Iartchouk N; Smith DI; Ross JS; Hoersch S; Shridhar V; Lillie J; Kaufmann SH; Clark EA; Damokosh AI
Clin Cancer Res; 2005 Mar; 11(6):2149-55. PubMed ID: 15788660
[TBL] [Abstract][Full Text] [Related]
11. Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.
Lindemann K; Kristensen G; Mirza MR; Davies L; Hilpert F; Romero I; Ayhan A; Burges A; Rubio MJ; Raspagliesi F; Huizing M; Creemers GJ; Lykka M; Lee CK; Gebski V; Pujade-Lauraine E
Ann Oncol; 2016 Aug; 27(8):1505-10. PubMed ID: 27407100
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value as a Biomarker.
Zhang X; Li H; Yu X; Li S; Lei Z; Li C; Zhang Q; Han Q; Li Y; Zhang K; Wang Y; Liu C; Mao Y; Wang X; Irwin DM; Guo H; Niu G; Tan H
Cell Physiol Biochem; 2018; 48(5):1983-1994. PubMed ID: 30092594
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.
Blassl C; Kuhlmann JD; Webers A; Wimberger P; Fehm T; Neubauer H
Mol Oncol; 2016 Aug; 10(7):1030-42. PubMed ID: 27157930
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy.
Aktas B; Kasimir-Bauer S; Heubner M; Kimmig R; Wimberger P
Int J Gynecol Cancer; 2011 Jul; 21(5):822-30. PubMed ID: 21613958
[TBL] [Abstract][Full Text] [Related]
15. [Identification and prognostic value of differentially expressed proteins of patients with platinum resistance epithelial ovarian cancer in serum].
Wu WJ; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Jul; 51(7):515-23. PubMed ID: 27465871
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
Jansaka N; Suprasert P
Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
[TBL] [Abstract][Full Text] [Related]
17. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
[TBL] [Abstract][Full Text] [Related]
18. HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
Wang Y; Li M; Meng F; Lou G
Hum Pathol; 2017 Feb; 60():114-120. PubMed ID: 27818289
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
20. Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.
Petrillo M; Zannoni GF; Beltrame L; Martinelli E; DiFeo A; Paracchini L; Craparotta I; Mannarino L; Vizzielli G; Scambia G; D'Incalci M; Romualdi C; Marchini S
Ann Oncol; 2016 Apr; 27(4):625-34. PubMed ID: 26782955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
